.Attribute Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin led to enhanced progression-free as well as total survival, bring about FDA commendation as well as a new therapy choice for patients.